AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04514835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin+Capecitabine+Sintilimab
Description: The first stage:concurrent chemoradiotherapy，cisplatin，25-30mg/m2 ivgtt d1;capecitabine,800mg/m2, bid d1-5，qw，5weeks;concurrent radiotherapy,1.8-2Gy/d，5d/W，50-50.4Gy.~second stage:Sintilimab, 200mg,q3w, a total of 3 times，Each infusion lasted for 30-60 min until disease progression or intolerable toxicity, with a maximum duration of no more than 12 months.
Study NCT05761509 — intervention group
Intervention type: DRUG
Intervention: Doravirine
Description: The study treatments will used during 28 days according to the routine care of each investigator center.
Study NCT04663802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Default order set
Description: With the default order set strategy, some mechanical ventilation order settings will be pre-populated to be consistent with LPV, including the mode and tidal volume, automatically calculated as 6 milliliters per kilogram of predicted body weight (cc/kg PBW; as determined by each patient's height and gender). The physician will have the option to opt out of any of the specified LPV settings and select other values.
Study NCT04309682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crestal sinus approach technique
Description: a Full thickness flap will be elevated at the edentulous site with two vertical releasing incision and then the preparation of osteotomy will be prepared following standard implant system protocol preparation of the osteotomy. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place and the implant itself will be used to gently elevate the sinus up to 3-5mm.
Study NCT04309682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral sinus approach
Description: a full-thickness flap will be elevated at the edentulous site with two vertical releasing incisions extending to the vestibule for better reflection and exposure to the lateral wall of the sinus. The lateral antrostomy will be prepared in the lateral sinus wall using rotary bur no. 8 to provide adequate access to remove the thin to thick cortical bone and to expose the thin sinus membrane. The membrane will be elevated across the sinus floor and up the medial wall and this elevation must extend anteriorly-posteriorly to provide the exposed sinus floor. Drilling will be done gently till reaching 0-1mm from the sinus floor, then implant placement will take place
Study NCT04697823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: use of hyaluronan-enriched transfer medium
Description: In the study group, an embryo transfer will be performed in hyaluronan-enriched transfer medium
Study NCT05984290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthokeratology lens
Description: Each subject will wear the study lenses in both eyes overnight for approximately 3 months.
Study NCT06421649 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy
Description: All patients will be offered radical adjuvant proton beam therapy to a dose of 60-66 Gray (Gy) in 30-33 fractions delivered Monday to Friday over 6-6.5 weeks.
Study NCT04875169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Core Treatment Active Experimental: SHR0302 Dose#1
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Study NCT04875169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Core Treatment Active Experimental: SHR0302 Dose#2
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 16 weeks
Study NCT04875169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Core Treatment Placebo Comparator: Placebo
Description: Drug: Placebo Oral tablets taken once daily (QD) for 16 weeks
Study NCT04875169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extension Treatment Active Experimental: SHR0302 Dose#1
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Study NCT04875169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extension Treatment Active Experimental: SHR0302 Dose#2
Description: Drug: SHR0302 Oral tablets taken once daily (QD) for 36 weeks
Study NCT05617950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: salicylic acid
Description: Salicylic acid is applied once daily by the patients (or parents) for a maximum of 12 weeks.
Study NCT05617950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: Cryotherapy is delivered by a technician up to a maximum of four treatments 3 weeks apart.
Study NCT03301805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLEX 404
Description: BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle~* 28 days a cycle.
Study NCT05185323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding usual known aids and osteopathic treatment
Description: Breastfeeding usual known aids and osteopathic treatment
Study NCT05185323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breastfeeding usual known aids
Description: Breastfeeding usual known aids
Study NCT05192967 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pandemic preparedness via video
Description: A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a video demonstration.
Study NCT05192967 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pandemic preparedness via classical method
Description: A training program created by experts on knowledge, attitude, skills, simulated case approach, communication between the patient and the team, and psychological resilience about COVID-19 was implemented with a classical method.
Study NCT05253846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: chemotherapy treatment
Study NCT05253846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: chemotherapy treatment
Study NCT05253846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lederfolin
Description: treatment
Study NCT05253846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: chemotherapy treatment
Study NCT05253846 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: RT
Study NCT05253846 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: surgery
Study NCT04663802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician-targeted accountable justification
Description: When a physician enters a mechanical ventilation order for a tidal volume that is greater than 6 cc/kg PBW, an alert will appear requiring the physician to enter a reason for choosing a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The physician will not be able to sign the mechanical ventilation order set until after a response is entered.
Study NCT04663802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory therapist (RT)-targeted accountable justification
Description: If an RT enters a tidal volume in a flowsheet documentation field value greater than 6 cc/kg PBW, an alert will appear requiring them to enter a reason for entering a setting inconsistent with LPV. Clinicians will be instructed to provide a reason for deviation from LPV settings and that their response will be maintained in the medical record. The RT will not be able to save the documentation in the EHR until after a response is entered.
Study NCT04598529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A2 milk
Description: a variety of cow's milk that contains only A2 beta-casein (and therefore lacks of A1 beta-casein).
Study NCT04598529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional milk
Description: cow's milk with a mixture of A1 and A2 beta-casein.
Study NCT06383351 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Two sets of questionnaires will be administered to patients:~* Questionnaire about their perception of peri-implant disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire.
Study NCT05825235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: 6 months of treatment with add-on Pramipexole
Study NCT06326528 — intervention group
Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Dapagliflozin 10 mg or Empagliflozin 25mg
Study NCT04927325 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Set of Photos
Description: A standardized set of photos will be taken with a tablet camera, SLR, thermal camera.
Study NCT05245851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Opportunistic screening for low BMD
Description: Software will analyze x-rays of the chest, thoracic spine, lumbar spine, pelvis, knee or hand/wrist acquired for any reason, and notify the radiologist at time of acquisition if low BMD is detected. The report to the radiologist includes the following statements:~* This x-ray was opportunistically analyzed by RhoTM, an investigational device under ITA \[investigational testing authorization\] from Health Canada, to screen for low bone mineral density (low BMD).~* This information should be used by a trained healthcare provider in conjunction with a patient's clinical fracture risk to determine if formal BMD screening with DXA is appropriate.~The radiologist can choose to include this as an incidental finding in their report to the referring physician.
Study NCT06166758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: Educational video regarding the benefits, risks, and limitations of genetic testing for hereditary cancer risk.
Study NCT04916613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide 300 mg
Description: 600 mg po, b.i.d.
Study NCT04916613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po, b.i.d.
Study NCT04916613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Description: Use according to local standard of care
Study NCT04916613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy
Description: Use according to local standard of care
Study NCT06368687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anorexia nervosa plus autism
Description: In the inpatient care the treatment model takes into account the patient's perception disorders, meaning e.g. an adapted mealtime situation where the patient can eat separately or wear hearing protection if necessary. The patients have an adapted meal plan regarding difficulties with specific textures or foods. To meet their need for continuity, they have the same contact persons throughout the entire period of care. The healthcare staff receive training in working with the specific subgroup and have regular exchanges of experience regarding the patient group, 15 minutes every or every two weeks.
Study NCT05523713 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Peripheral venous blood samples
Description: 10 ml in a sodium heparin tube and 5 ml in an EDTA tube
Study NCT04724369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-MFBG
Description: Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
Study NCT05873556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)
Description: This is an online personalized feedback intervention that contains information summarizing participants' desire to drink, mood, willingness to drink, and alcohol demand as reported before and after alcohol exposure.
Study NCT05984641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONAN® Proctological Cream
Description: The active treatment samples used for the duration of the study were allocated at the site involved and consisted in 30 g tubes with an endorectal applicator, identified by the batch number, expiry date and information on the study on dedicated labels. The treatment of patients randomized to Group A consisted in applying the local treatment (1 application 3 times/day) for 30 days. Instrutction to an healthy diet including an adequate fibre intake and general advice for facilitating evacuation using stool softeners.
Study NCT05663359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EVLA 1940 nm
Description: Treatment of varicose veins by endothermic ablation with an endovenous laser at 1940 nm
Study NCT05663359 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EVLA 1470 nm
Description: Treatment of varicose veins by endothermic ablation with an endovenous laser at 1470 nm
Study NCT06553274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized nutrition intervention
Description: After the patients were enrolled, they were given nutritional assessment by full-time clinical nutritionist and designed individualized nutritional management program, which included: Nutritional Assessment once a week for 4 weeks after Transplantation + 30 days, and nutritional assessment once a week for 4 weeks after Transplantation + 60 days, nutritional assessment every 2 weeks for 8 weeks; nutritional assessment every 4 weeks for 1 year after Transplantation + 120 days after transplantation; nutritional assessment during hospitalization in the ward and after discharge from the hospital, they were followed up in the nutrition counseling clinic or by telephone. The total energy intake was 25-35 kcal/kg/d and the protein intake was 1.2-1.5 g/kg/d. According to theFive-step nutritional treatment principle, individual nutritional prescriptions were designed by clinical nutritionists.
Study NCT05348265 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity steady state training
Description: Intervention will be provided for a period of 8 weeks. For the first 4 weeks the intervention will consist of 35-40 minutes of supervised slow paced treadmill walk, five days a week. From week 5 till 8 the intervention will consist of 50-60 minutes of supervised slow paced treadmill walk, five days a week.
Study NCT05348265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Intervention will be provided for a period of 8 weeks, thrice a week. Intervention will start with a 5 minutes warm up period of jogging in place. For the first 4 weeks, 3 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.~Intervention will start with a 5 minutes warm up period of jogging in place. For weeks 5 to 8, 4 series of these exercises will be performed with 3 minutes of rest in between: 30 seconds burpees + 30 seconds recovery, 30 seconds lunges + 30 seconds recovery, 30 seconds skipping + 30 seconds recovery, 30 seconds squats + 30 seconds recovery.~Exercise session will be followed by a cool down of 5 to 10 minutes with upper and lower extremity stretches.
Study NCT04742946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Physiotherapy Practice (Telerehabilitation)
Description: Online Physiotherapy services
Study NCT06315543 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink water
Description: Increase drinking water by 1650mL per day (3 bottles of 550mL bottled water)
Study NCT04930432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCLA-129
Description: MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
Study NCT05569967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal stabilization training through telerehabilitation
Description: Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
Study NCT05569967 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spinal stabilization training face-to-face
Description: Individuals in both groups will receive spinal stabilization training 3 times a week for 8 weeks.
Study NCT05962268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video based education
Description: The video was prepared by the researchers in line with the literature. Expert opinion was obtained from 10 individuals with at least a doctorate and studies on the subject of video content. In line with expert opinions, the video content was updated and finalized. Patient education with the prepared video was provided by one of the researchers involved in the study. The video education took 20 minutes in total.
Study NCT05962268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face to face education
Description: The patients were trained on fistula care by the researcher. Fistula care training was given to the patients in the control group using face-to-face education technique. In this training, researcher verbally explained fistula care to patients. The training was conducted one-on-one with the patient in the patient's room and lasted 10 minutes. The training was presented to the patient through the lecture method. The training was also supported by the question-and-answer method. The training was given twice, one week apart, when patients came for hemodialysis treatment after the condition of the patients on dialysis stabilized.
Study NCT06255782 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ECUR-506
Description: ECUR-506 is a gene editing treatment delivering a gene encoding the editing enzyme and an OTC gene.
Study NCT05092412 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.
Study NCT05092412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.
Study NCT05092412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide, and cisplatin/carboplatin
Description: Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.
Study NCT05399706 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CTA Aorta
Description: Computed Tomography Angiography - Aorta Whole
Study NCT05589116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Compassionate Imagery Intervention
Description: The intervention comprises 14 pre-recorded, 10-15 minute videos. Participants will be asked to watch one video per day over a two-week period. The videos initially focus on providing psychoeducation about what self-compassion is, before delivering a series of guided Compassion Focused Therapy (CFT) informed exercises to cultivate self-compassion. The first week of the intervention will teach key compassion skills, with the second week focusing on skill consolidation.
Study NCT06416059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: The mobile application is a culturally adapted, brief, personalized feedback intervention (PFI) to address alcohol misuse in the context of clinical anxiety,
Study NCT06108427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Renin measurements
Description: Use of plasma renin measurements to guide MRA dosing, aiming for plasma renin unsuppression
Study NCT05436613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: tDCS at 2mA in 30 minute sessions for 5 sessions per week for 3 weeks and then 2 sessions per week for 3 weeks.
Study NCT05838664 — intervention group
Intervention type: DRUG
Intervention: No OAC
Description: AF Patient who were not exposed to oral anticoagulation
Study NCT05838664 — intervention group
Intervention type: DRUG
Intervention: VKA
Description: AF patients who received VKA
Study NCT04285827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL889
Description: Administered as an IV infusion
Study NCT05838664 — intervention group
Intervention type: DRUG
Intervention: apixaban
Description: AF patients who received apixaban
Study NCT05838664 — intervention group
Intervention type: DRUG
Intervention: rivaroxaban
Description: AF patients who received rivaroxaban
Study NCT05838664 — intervention group
Intervention type: DRUG
Intervention: dabigatran
Description: AF patients who received dabigatran
Study NCT04822129 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual will provide participants with basic information that is readily available as well as the encouragement to develop a brain health program that may be available from medical professionals.
Study NCT04822129 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogtrastim Model
Description: The study intervention for this group will include a review of the Cogtrastim model and explicit discussion of the possible mechanisms of action of various activities that have been shown to be associated with better health in general and, where supported by evidence, better mental functioning in older persons. Persons in this group will be encouraged to select brain health activities based on the model.